Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA; Gynecologic Oncology Group Study.

Gynecol Oncol. 2008 Dec;111(3):455-60. doi: 10.1016/j.ygyno.2008.07.049. Epub 2008 Sep 30.

PMID:
18829087
2.

Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?

Maxwell GL, Tian C, Risinger JI, Hamilton CA, Barakat RR; Gynecologic Oncology Group Study.

Cancer. 2008 Sep 15;113(6):1431-7. doi: 10.1002/cncr.23717.

3.

Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Look KY, Blessing JA, Michener CM, Rubin S, Ramirez PT; Gynecologic Oncology Group Study.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):773-8.

PMID:
17892452
4.

Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Garcia AA, Blessing JA, Vaccarello L, Roman LD; Gynecologic Oncology Group Study.

Am J Clin Oncol. 2007 Aug;30(4):428-31.

PMID:
17762444
5.

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP; Gynecologic Oncology Group Study.

J Clin Oncol. 2007 Aug 20;25(24):3621-7.

PMID:
17704411
6.

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.

McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH; Gynecologic Oncology Group study.

Gynecol Oncol. 2007 Jul;106(1):16-22.

PMID:
17574073
7.

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.

Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A; Gynecologic Oncology Group study.

Gynecol Oncol. 2007 Jul;106(1):221-32. Epub 2007 May 3.

PMID:
17481705
8.

Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.

Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR; Gynecologic Oncology Group study.

Cancer. 2006 Nov 1;107(9):2197-205.

9.

Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.

Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study.

J Clin Oncol. 2006 Feb 1;24(4):587-92.

PMID:
16446331
10.

Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study.

J Clin Oncol. 2006 Jan 1;24(1):36-44. Epub 2005 Dec 5.

PMID:
16330675
11.

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study.

J Clin Oncol. 2005 Jul 20;23(21):4626-33. Epub 2005 May 23.

PMID:
15911865
12.

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

Monk BJ, Huang HQ, Cella D, Long HJ 3rd; Gynecologic Oncology Group Study.

J Clin Oncol. 2005 Jul 20;23(21):4617-25. Epub 2005 May 23. Erratum in: J Clin Oncol. 2005 Nov 20;23(33):8549.

PMID:
15911864
13.

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A; Gynecologic Oncology Group study.

Gynecol Oncol. 2004 Feb;92(2):639-43.

PMID:
14766259
14.

Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Look KY, Bookman MA, Schol J, Herzog TJ, Rocereto T, Vinters J; Gynecologic Oncology Group Study.

Gynecol Oncol. 2004 Jan;92(1):93-100.

PMID:
14751144
15.

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W; Gynecologic Oncology Group study.

Gynecol Oncol. 2004 Jan;92(1):10-4.

PMID:
14751131
16.

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB; Gynecologic Oncology Group study.

Gynecol Oncol. 2004 Jan;92(1):4-9.

PMID:
14751130
17.

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.

Armstrong DK, Blessing JA, Rader J, Sorosky JI; Gynecologic Oncology Group Study.

Invest New Drugs. 2003 Nov;21(4):453-7.

PMID:
14586213
18.

Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Havrilesky L, Darcy kM, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A; Gynecologic Oncology Group Study.

J Clin Oncol. 2003 Oct 15;21(20):3814-25.

PMID:
14551300
19.

Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W; Gynecologic Oncology Group Study.

J Clin Oncol. 2003 Oct 15;21(20):3808-13.

PMID:
14551299
20.

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.

Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL; Gynecologic Oncology Group Study.

Gynecol Oncol. 2003 Apr;89(1):148-54.

PMID:
12694669

Supplemental Content

Loading ...
Support Center